How much of vTv Therapeutics'stock is owned by insiders?
Specifically, they have bought $0.00 in company stock and sold $100,050.00 in company stock. Only 1.40% of the stock of vTv Therapeutics is held by insiders. Only 5.22% of the stock of vTv Therapeutics is held by institutions. Earnings for vTv Therapeutics are expected to decrease in the coming year, from ($0.18) to ($0.32) per share.
Is vTv Therapeutics (VTV) a good buy on negative earnings?
Only 5.22% of the stock of vTv Therapeutics is held by institutions. Earnings for vTv Therapeutics are expected to decrease in the coming year, from ($0.18) to ($0.32) per share. The P/E ratio of vTv Therapeutics is -9.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is vTv Therapeutics (VTVT) set for a trend reversal?
TTP399 is vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
What is the upside for vTv Therapeutics'stock?
1 brokers have issued 12 month price objectives for vTv Therapeutics' shares. Their forecasts range from $6.00 to $6.00. On average, they expect vTv Therapeutics' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 615.1% from the stock's current price.
Is VTVT a good stock to buy now?
The consensus among 1 Wall Street analyst covering (NASDAQ: VTVT) stock is to Strong Buy VTVT stock.
Why did VTVT stock go up?
vTv Therapeutics (VTVT) has strong positive catalysts in the medium term and the long term. Novavax (NVAX) looks poised to be boosted by an upcoming FDA approval of its coronavirus shot. Aileron (ALRN) has reported positive data and has a huge potential market Biotech stocks have tumbled in recent months and years.
Should I buy vTv Therapeutics?
The consensus among Wall Street analysts is that investors should "buy" vTv Therapeutics stock. View analyst ratings for vTv Therapeutics or view top-rated stocks.
Should I buy or sell vTv Therapeutics stock right now?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2...
What is vTv Therapeutics' stock price forecast for 2022?
2 brokerages have issued 1 year price targets for vTv Therapeutics' stock. Their forecasts range from $5.00 to $6.00. On average, they predict vTv...
How has vTv Therapeutics' stock price performed in 2022?
vTv Therapeutics' stock was trading at $0.9950 at the beginning of the year. Since then, VTVT shares have decreased by 29.6% and is now trading at...
When is vTv Therapeutics' next earnings date?
vTv Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for vT...
How were vTv Therapeutics' earnings last quarter?
vTv Therapeutics Inc. (NASDAQ:VTVT) issued its earnings results on Tuesday, March, 29th. The biotechnology company reported ($0.08) earnings per sh...
Who are vTv Therapeutics' key executives?
vTv Therapeutics' management team includes the following people: Ms. Deepa Prasad , Strategic Advisor (Age 42, Pay $667.13k) Mr. Richard S. Nels...
Who are some of vTv Therapeutics' key competitors?
Some companies that are related to vTv Therapeutics include Pliant Therapeutics (PLRX) , InterCure (INCR) , Tyra Biosciences (TYRA) , Biomea Fu...
What other stocks do shareholders of vTv Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV)...
When did vTv Therapeutics IPO?
(VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and...
About vTv Therapeutics
vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer.
News & Analysis: vTv Therapeutics (Class A)
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock.
Environmental, Social, and Governance Rating
There is no available coverage of vTv Therapeutics (Class A) at this time.
vTv Therapeutics
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
About VTVT
Some stock charts might currently not be supported. To try again, please refresh this page.
Rating
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer.
Signals & Forecast
What analysts recommend for this stock, on a scale from 1 (buy) to 5 (sell).
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Monday, February 14, 2022, and so far it has risen 11.55%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Is vTv Therapeutics Inc. stock A Buy?
vTv Therapeutics Inc. finds support from accumulated volume at $0.77 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in vTv Therapeutics Inc
vTv Therapeutics Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
About vTv Therapeutics Inc
In the last 100 trades there were 37.8 million shares bought and 110.37 thousand shares sold. The last trade was done 65 days ago by Perelman Ronald O who sold 87 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
